How did Bal Pharma's Q4 financial performance look?

The company reported a standalone net profit of ₹3.70 crore, a 34% decrease from the ₹5.61 crore recorded in the same quarter last year. Revenue from operations saw a marginal increase to ₹83.92 crore from ₹81.78 crore.

What is the scale of the proposed warrant issue?

The board approved the issuance of 1,000,000 warrants to promoters on a preferential basis. This represents a potential dilution of approximately 6.3% for the company.

What dividend has the board recommended?

The board recommended a dividend of ₹1.20 per share, which equates to a 12% payout.

Are there other corporate governance changes?

Yes, the company appointed a new company secretary and approved the grant of 500,000 stock options to employees.

Earnings · Pharmaceuticals · Micro cap

Bal Pharma profit drops 34% as board approves promoter warrant issue

Standalone net profit fell to ₹3.70 crore in Q4, while the board cleared a preferential issue of 1,000,000 warrants to promoters.

— 1 earlier story on Bal Pharma Ltd. →

BALPHARMA 27 May 2026 · 6:55 PM IST Verify on BSE · NSE

Mkt cap₹154 cr

P/E18.90×

ROE9.32%

Debt / eq.1.94

Div yld1.30%

34% Year-on-year decline in standalone net profit for Q4 FY2026.

What's new

Standalone net profit fell to ₹3.70 crore from ₹5.61 crore a year ago.
Board approved issuing 1,000,000 warrants to promoters on a preferential basis.
Dividend recommended at ₹1.20 per share.

Why this matters

The profit contraction shows margin pressure despite a slight uptick in revenue. The warrant issue signals a capital injection from promoters, which will dilute existing shareholders by approximately 6.3%.

What we're watching

Shareholder approval process for the warrant issue via postal ballot.
Execution of the 500,000 employee stock options.
Whether the dividend payout impacts liquidity for upcoming growth plans.

The full read

Bal Pharma saw its standalone net profit slide 34% to ₹3.70 crore for the quarter ended March 31, 2026, down from ₹5.61 crore in the prior year. Revenue growth remained sluggish, rising only marginally to ₹83.92 crore from ₹81.78 crore.

Margins are under pressure.

To shore up capital, the board approved the issuance of 1,000,000 warrants to promoters on a preferential basis. This move, which requires shareholder approval via postal ballot, represents a potential dilution of roughly 6.3%. Alongside the capital raise, the board recommended a dividend of ₹1.20 per share. The company also refreshed its administrative ranks with a new company secretary and authorized 500,000 employee stock options. The upcoming postal ballot is the next test for the company's capital structure.

Questions answered

How did Bal Pharma's Q4 financial performance look?: The company reported a standalone net profit of ₹3.70 crore, a 34% decrease from the ₹5.61 crore recorded in the same quarter last year. Revenue from operations saw a marginal increase to ₹83.92 crore from ₹81.78 crore.
What is the scale of the proposed warrant issue?: The board approved the issuance of 1,000,000 warrants to promoters on a preferential basis. This represents a potential dilution of approximately 6.3% for the company.
What dividend has the board recommended?: The board recommended a dividend of ₹1.20 per share, which equates to a 12% payout.
Are there other corporate governance changes?: Yes, the company appointed a new company secretary and approved the grant of 500,000 stock options to employees.

Mentioned: Bal Pharma Ltd. · 1,000,000 warrants · ₹3.70 crore

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on BALPHARMA →

27 May 2026 · 6:55 PM IST Bal Pharma profit drops 34% as board approves promoter warrant issue
today Bal Pharma profit slips 34% as board approves promoter warrants